VERA

Vera Therapeutics, Inc.

BS score 35.2LOWPHASE3 · mkt cap $2.92B · rev ttm $0

drug hypothesis

Atacicept modulates BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) - TACI-Fc fusion protein to treat IgA Nephropathy (IgAN).

moa:Atacicept is a TACI-Fc fusion protein that binds to BAFF and APRIL, inhibiting B-cell activation and survival, thereby reducing production of pathogenic galactose-deficient IgA1 (Gd-IgA1) antibodies that drive IgA nephropathy

score breakdown

trial design35

base rate disconnect13

language red flags80

composite35.2

valuation analysis

market cap$2.92B

revenue ttm$0

phasePHASE3

historical base rate42%

disconnect ratio0.5x

lead trialNCT07020923

meta

cik0001831828

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase 2, randomized, placebo-controlled trial enrolling 90 patients with IgA Nephropathy. Monthly dosing of atacicept at different regimens. Primary completion expected September 2026.

primary endpoint:Evaluate the effect of atacicept on Gd-IgA1 in patients with IgAN (Up to 24 weeks)

claimed differentiation

Not stated in provided data - SEC filing business section appears empty/minimal

language red flags

Limited data provided - SEC filing business section appears to contain minimal information
No stated differentiation claims visible in provided materials
No preclinical evidence summary included in the trial data
Company claims and risk factors not extractable from the minimal SEC filing content provided

company-stated risks

Standard clinical trial risks (adverse events, lack of efficacy) - not explicitly detailed in provided data
B-cell depletion may increase infection risk
Immunoglobulin reduction (IgA, IgG, IgM) monitored as secondary endpoint - potential for hypogammaglobulinemia

upcoming catalysts

2026-09Primary trial completion
Q4 2026 (estimated)Topline data release